A three-year prospective study on the RefluxStop implant for gastroesophageal reflux disease (GERD) revealed outstanding outcomes. Among 47 patients, there were no device-related adverse events or need for proton pump inhibitors post-treatment. The median GERD-HRQL score improved by 93.1%, while daily regurgitation decreased by 97.9%. Additionally, incidences of bothersome dysphagia dropped significantly, with complete resolution of baseline odynophagia. These results affirm the safety and effectiveness of RefluxStop in restoring normal gastroesophageal junction function.
Journal Article by Harsányi L, Kincses Z and Altorjay Á in Dig Dis Sci
© 2024. The Author(s).